Brewer reportedly asked alumni and former players to come home for the season-ending game against Kansas. Faurot won 100 games, and is credited with creating the split-T formation, precursor of the wishbone and veer offenses.- While the infamous Fifth down game against CU still rankles the Missouri faithful, most of their venom is saved for Kansas. The bitter feelings over the 1960 game, above, only added fuel to the fire. The Border War as it was long known, is now known as the Border Showdown, a nod to the post 9/11 era.- Missouri leads the all-time series against Colorado, 40-31-3.
The series was much more lopsided in the Tigers favor, though, until recently. Prior to the 1985 season, Missouri had a dominating 31-13-3 lead. The Buffs then ran off a 12 game win streak, and have won 18 of the last 27 in the series.- Missouri ties to Boulder include head coaches Bill McCartney, a 1962 MU graduate who played on that 1960 team, and Gary Barnett, a 1969 MU alumnus.- famous alumni football Dan Devine (coach), Kellen Winslow, Henry Marshall, Phil Bradley, Tony Galbreath, Roger Wehrli, Andy Russell, Mel Gray (and now Jeremy Maclin, Chase Daniel, and Chase Coffman from the class of 2008).- famous alumni other George C. Scott (actor), Sheryl Crow (singer), Mort Walker (cartoonist). This article is also featured on CU At The Game. CHICAGO (Reuters) - Users of Alli, the first weight-loss drug approved for sale over-the-counter in the United States, are finding what they likely suspected all along: pills are no magic substitute for diet and exercise.Yet as Americans engage in the New Year's tradition of resolving to shed pounds, the market for diet aids is expected to remain firm, even as the economy is mired in recession.Americans spend $30 billion a year on weight-loss products and services, and two-thirds of the population is overweight or obese.GlaxoSmithKline's Alli, a lower-strength version of Roche's prescription-only Xenical, created' a stir when it was approved 18 months ago.Since then, it has become known for its unpleasant side effects, including incontinence, diarrhea and flatulence with "oily spotting.""It works to inhibit absorption of fat from our diet.
But, he added, the intended effect "is also overrated.""People who took the drug lost only 4 more pounds (1.8 kg) than the placebo group after a year. People have to ask themselves whether the expense of this medicine is worth a few extra pounds," Hensrud said.A 30-day supply of Alli costs $60.People who took Xenical, the prescription strength version, lost an average of 5 to 7 additional pounds (2.2 to 3.2 kg) after a year compared with those who took a placebo.Still, experts say weight loss of 5 percent to 10 percent is a worthy goal and a point where health improves.Meanwhile, Alastair Wood, who chaired the Food and Drug Administration advisory panel that reviewed Alli in 2006, said he's not convinced the drug is being used by the people who would benefit most. FDA rejected it in 2007 on concerns it causes neurological and psychiatric problems.There are few promising treatments in the pipeline at a time when obesity is emerging as one of the biggest health crises facing the developed world.Earlier this month, Orexigen Therapeutics unveiled results from a late-stage trial of its experimental drug Contrave, which fell short of the bar set by U.S. regulators.Another candidate is Arena Pharmaceuticals' lorcaserin. A mid-stage trail showed the drug fared well in helping patients lose weight. Late-stage results are due in March.Pfizer, one of several drug makers to drop development of a weight-loss drug from a once promising class that was found to cause psychiatric side effects, said it continues to pursue obesity treatments."Some of the late-stage products ... not just Pfizer's pipeline but several other companies' pipelines, have not been successful," Pfizer Chief Executive Jeff Kindler told the Reuters Health Summit in November."It involves so many different aspects.